Amneal Plans ‘Meaningful Additions’ To Its Generics Portfolio
As Company Sees Increase In Its Generics Sales And Overall Revenues
Amneal continues to focus on new generics launches as the company sees its quarterly and half-yearly revenues increase on the back of its new launches and generics portfolio. The US-based company said that it was looking to continue its shift towards complex generics, as it considers eventually building in-house capabilities for biosimilars.
